HWK-007
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Endometrial Cancer
Conditions
Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent, Non-squamous EGFR Wt NSCLC, Platinum Resistant Ovarian Cancer, PROC
Trial Timeline
Dec 19, 2025 → Dec 1, 2028
NCT ID
NCT07444814About HWK-007
HWK-007 is a phase 1 stage product being developed by Whitehawk Therapeutics for Endometrial Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07444814. Target conditions include Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic.
What happened to similar drugs?
0 of 20 similar drugs in Endometrial Cancer were approved
Approved (0) Terminated (0) Active (20)
Hype Score Breakdown
Clinical
6
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07444814 | Phase 1 | Recruiting |
Competing Products
20 competing products in Endometrial Cancer